User Tools

Site Tools


respiratory:beta2_agonists:saba

Short-Acting β2 Agonists (SABA)

respiratory bronchodilator beta2_agonist saba

Short-acting β2 agonists are rapid bronchodilators used for immediate relief of bronchospasm.

They are the primary rescue medications in obstructive lung disease.

SABA = symptom relief They do NOT control inflammation


Drugs in Class

Mechanism of Action

Receptor

  • β2 adrenergic receptor activation

Cellular Effect

  • ↑ cAMP
  • Smooth muscle relaxation

Physiologic Effects

  • Bronchodilation
  • ↓ airway resistance
  • ↓ mast cell mediator release
  • ↑ mucociliary clearance
  • Intracellular potassium shift

Net effect:

  • Rapid airway opening

Clinical Role

Primary uses:

  • Acute asthma symptoms
  • Exercise-induced bronchospasm
  • COPD rescue therapy

Also used for:

  • Hyperkalemia (temporary intracellular shift)

SABA should always be paired with controller therapy in persistent asthma:


Dosing Concept

Situation Meaning
Rare use Controlled disease
>2 days/week Inadequate control
Daily use Needs escalation

Frequent rescue inhaler use is a marker of worsening airway inflammation — not a need for more bronchodilator.


Adverse Effects

Effect Mechanism
Tremor Skeletal muscle β2 stimulation
Tachycardia β1 spillover
Hypokalemia Intracellular potassium shift
Anxiety Adrenergic stimulation

Dose dependent.


Clinical Pearls

The rescue inhaler measures disease control.

More SABA = more inflammation

  • First drug used in asthma exacerbation
  • Spacer improves delivery significantly
  • Nebulizer is easier, not stronger
  • Overuse predicts hospitalization risk

Comparison Within β2 Class

Class Role Duration
SABA Rescue 4–6 hr
LABA Maintenance 12–24 hr

respiratory/beta2_agonists/saba.txt · Last modified: by andrew2393cns